Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression

This phase 2a, randomized, multicenter, double-blind, proof-of-concept study was designed to evaluate, efficacy, safety and tolerability of JNJ-40411813/ADX71149, a novel metabotropic glutamate 2 receptor positive allosteric modulator as an adjunctive treatment for major depressive disorder (MDD) with significant anxiety symptoms. Eligible patients (18-64 years) had a DSM-IV diagnosis of MDD, Hamilton Depression Rating Scale-17 (HDRS17) score of >= 18, HDRS17 anxiety/somatization factor score of >= 7, and an insufficient response to current treatment with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor. The doubly-randomized, 8-week double-blind treatment phase was comprised of two 4-week periods, from which a combined test statistic was generated, with pre-determined weights assigned to each of the 2 treatment periods. Period 1: patients (n = 121) were randomly assigned (1: 1) to JNJ-40411813 (n = 62; 50 mg to 150 mg b.i.d, flexibly dosed) or placebo (n = 59); Period 2: placebo-treated patients (n = 22) who continued to meet entry severity criteria were re-randomized (1: 1) to JNJ-40411813 or placebo, while other patients underwent sham re-randomization and continued on their same treatment. Of 121 randomized patients, 100 patients (82.6%) were completers. No efficacy signal was detected on the primary endpoint, the 6-item Hamilton Anxiety Subscale (HAM-A(6), p = 0.51). Efficacy signals (based on prespecified 1-sided p < 0.20) were evident on several secondary outcome measures of both depression (HDRS17 total score, 6-item subscale of HDRS1(7) assessing core depressive symptoms [HAM-D-6], and Inventory of Depressive Symptomatology [IDS-C-30]) and anxiety (HDRS17 anxiety/somatization factor, IDS-C-30 anxiety subscale). Although well-tolerated, the results do not suggest efficacy for JNJ-40411813 as an adjunctive treatment for patients with MDD with significant anxious symptoms in the dose range studied. (C) 2016 Elsevier Inc. All rights reserved.